An acquired clonal disorder of complement regulation; terminal complement and proximal C3 inhibitors control haemolysis.
Myeloproliferative neoplasm with erythrocytosis and thrombosis risk.
A thrombotic microangiopathy from ADAMTS13 deficiency; urgent plasma exchange with immunosuppression is the mainstay, with a targeted adjunct.
An inherited haemoglobin disorder; disease-modifying drugs and, increasingly, curative gene therapies are available.
A clonal mast-cell disorder spanning indolent to advanced forms; KIT-targeted therapy is available.
Sign in to your account
Remember me
